Seoul Economic Daily EnglishCodex · 实盘不做把握 6/10
北京时间·🕒 发布 15:03:25时区推断·⟳ 抓取 15:25:44·⚡ 决策 07-24 15:27:05 +1m21s·95.2 天前
Celltrion申报Zymfentra类风湿关节炎适应症欧洲三期试验
Zymfentra扩大至类风湿关节炎适应症方向上利好Celltrion，但当前只是三期试验申报/推进，不是获批或商业化落地。
📄 原文Seoul Economic Daily English↗ 原文
Celltrion Files for European Phase 3 Trial of Zymfentra for Rheumatoid Arthritis
Celltrion (068270.KS) has filed a global Phase 3 clinical trial plan for its subcutaneous infliximab formulation "CT-P1…
不做 Celltrion（068270.KS）
Zymfentra扩适应症方向利好但仍是三期申报/推进，欧盟登记显示相关项目早已存在，且对约39.6万亿韩元市值公司的短线收入增量无法量化；韩国收盘后不追。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- CT-P13 SC类风湿关节炎三期试验在欧盟临床登记中已显示2024年启动，削弱本次新闻的全新预期差。
- 媒体报道Celltrion称已向EMA提交Zymfentra类风湿关节炎全球三期临床试验计划。市场反应:韩国市场已收盘，Celltrion当日收177600韩元、涨3.14%。
- 收盘价177600韩元，前收172200韩元，当日涨3.14%，但该涨幅发生在新闻时间前的正常交易时段。市场反应:当日放量上涨，隔夜追单缺少未反应价格窗口。
关键理由
- Zymfentra扩大至类风湿关节炎适应症方向上利好Celltrion，但当前只是三期试验申报/推进，不是获批或商业化落地。
- Celltrion 2025年收入约4.16万亿韩元、2026年目标5.3万亿韩元，本事件新增收入仍需完成52周试验并获批后才可能体现，短线量级不足。
- 欧盟临床试验登记显示相关CT-P13 SC类风湿关节炎三期项目早在2024年已登记并启动，新闻新鲜度和预期差弱。
主要风险
- 若后续直接披露RA适应症获批、医保/处方放量或明确销售指引，再作为新催化重判。
- 事件发生在韩国收盘后，但标的当日已上涨3.14%，隔夜追高容易遇到利好兑现。
原文全文
展开原文 · 1,466 字
Celltrion (068270.KS) has filed a global Phase 3 clinical trial plan for its subcutaneous infliximab formulation "CT-P13 SC (Zymfentra)" in patients with rheumatoid arthritis with the European Medicines Agency (EMA), the company said in a regulatory filing on the 24th.
The trial is designed to evaluate the efficacy and safety of CT-P13 SC in patients with moderate to severe active rheumatoid arthritis.
Celltrion plans to conduct the Phase 3 trial in a randomized, placebo-controlled, double-blind, parallel-group design involving a total of 296 patients. The treatment period is 52 weeks.
The primary objective of the trial is to demonstrate that CT-P13 SC shows superior efficacy compared to placebo based on "ACR50," which represents a 50% improvement in symptoms according to American College of Rheumatology criteria, at week 12 of treatment.
CT-P13 SC was developed as a subcutaneous formulation of the infliximab biosimilar "Remsima IV." Unlike the intravenous injection method that requires a hospital visit, it can be administered subcutaneously, enhancing patient convenience in dosing.
CT-P13 SC has completed Phase 3 trials in adult patients with ulcerative colitis and Crohn's disease and has obtained marketing approval in several countries, including the United States and Europe.
Through this Phase 3 trial, Celltrion plans to expand the indications for CT-P13 SC to rheumatoid arthritis, following its existing use for inflammatory bowel disease.
The trial is designed to evaluate the efficacy and safety of CT-P13 SC in patients with moderate to severe active rheumatoid arthritis.
Celltrion plans to conduct the Phase 3 trial in a randomized, placebo-controlled, double-blind, parallel-group design involving a total of 296 patients. The treatment period is 52 weeks.
The primary objective of the trial is to demonstrate that CT-P13 SC shows superior efficacy compared to placebo based on "ACR50," which represents a 50% improvement in symptoms according to American College of Rheumatology criteria, at week 12 of treatment.
CT-P13 SC was developed as a subcutaneous formulation of the infliximab biosimilar "Remsima IV." Unlike the intravenous injection method that requires a hospital visit, it can be administered subcutaneously, enhancing patient convenience in dosing.
CT-P13 SC has completed Phase 3 trials in adult patients with ulcerative colitis and Crohn's disease and has obtained marketing approval in several countries, including the United States and Europe.
Through this Phase 3 trial, Celltrion plans to expand the indications for CT-P13 SC to rheumatoid arthritis, following its existing use for inflammatory bowel disease.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。